Last reviewed · How we verify
Cotellic — Competitive Intelligence Brief
marketed
Kinase Inhibitor
Dual specificity mitogen-activated protein kinase kinase 1
Oncology
Live · refreshed every 30 min
Target snapshot
Cotellic (cobimetinib) — Roche. Cotellic works by blocking the activity of two proteins, BRAF and MEK, which are involved in the growth and spread of cancer cells.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cotellic TARGET | cobimetinib | Roche | marketed | Kinase Inhibitor | Dual specificity mitogen-activated protein kinase kinase 1 | 2015-01-01 |
| Mektovi | mek162 | Pfizer | marketed | Dual specificity mitogen-activated protein kinase kinase 1 | 2018-01-01 | |
| Hernexeos | ZONGERTINIB | Boehringer Ingelheim | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Wayrilz | RILZABRUTINIB | Genzyme Corp | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Itovebi | INAVOLISIB | Genentech Inc | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| Romvimza | VIMSELTINIB | Deciphera Pharms | marketed | Kinase Inhibitor [EPC] | 2025-01-01 | |
| LAZERTINIB | LAZERTINIB | marketed | Kinase Inhibitor [EPC] | 2024-01-01 |
Recent regulatory actions (last 90 days)
- — Hernexeos · FDA · approved · US · Boehringer Ingelheim
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Mektovi · 9850229 · US
- — Mektovi · 10005761 · US
- — Mektovi · 9314464 · US
- — Mektovi · 9562016 · US
- — Mektovi · 9598376 · US
- — Mektovi · 9980944 · US
Sponsor landscape (Kinase Inhibitor class)
- Novartis · 5 drugs in this class
- Pfizer · 3 drugs in this class
- Bayer · 2 drugs in this class
- Boehringer Ingelheim · 2 drugs in this class
- Hoffmann-La Roche · 1 drug in this class
- Exelixis Inc · 1 drug in this class
- Novartis Pharm · 1 drug in this class
- Osi Pharms · 1 drug in this class
- Exelixis · 1 drug in this class
- Roche · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cotellic CI watch — RSS
- Cotellic CI watch — Atom
- Cotellic CI watch — JSON
- Cotellic alone — RSS
- Whole Kinase Inhibitor class — RSS
Cite this brief
Drug Landscape (2026). Cotellic — Competitive Intelligence Brief. https://druglandscape.com/ci/cobimetinib. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab